103 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
61 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / Industry / NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 1486
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01809691
62 Not yet recruiting Internet-Based Weight-Loss Program for Colorectal Cancer Survivors
Conditions: Cancer Survivor;   Colorectal Cancer;   Weight Changes
Intervention: Behavioral: Internet weight loss intervention
Study Type: Interventional
Phase:
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Health Services Research;   Masking: Open Label
Number Enrolled: 60
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01032590
63 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 36
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01303341
64 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 175
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01836029
65 Recruiting A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Condition: HER2+ Metastatic Breast Cancer (MBC)
Interventions: Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 600
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01808573
66 Recruiting Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Conditions: Bladder Cancer;   Urothelial Carcinoma
Interventions: Drug: OGX-427;   Drug: Docetaxel
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 200
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01780545
67 Recruiting Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Condition: Bladder Cancer
Interventions: Biological: TICE Bacillus Calmette-Guerin (BCG);   Biological: PANVAC
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH / Other
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 54
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02015104
68 Not yet recruiting Adjuvant Sequential Intravesical BCG and Electromotive Mitomycin-C (EMDA/MMC) After Transuretheral Resection in Patients With Primary High Risk Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder. A One-group Phase II Study.
Condition: Bladder Carcinoma
Intervention: Device: Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
Study Type: Interventional
Phase:
Funder Type: Other
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 50
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT02202044
69 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
Study Type: Expanded Access
Phase:
Funder Type: Industry
Study Design:
Number Enrolled:
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01947608
70 Recruiting Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: 300 mg Oral Azacitidine;   Drug: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 460
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01757535
71 Recruiting A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: GM-CSF;   Other: GM-CSF Placebo;   Biological: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Caregiver,  Investigator,  Outcomes Assessor)
Number Enrolled: 1200
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01322490
72 Recruiting Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 2
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 148
Gender: Male
Age Groups: Adult / Senior
NCT Number: NCT01576172
73 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Double Blind (Subject,  Investigator)
Number Enrolled: 180
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01575548
74 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Study Type: Observational
Phase:
Funder Type: Other
Study Design: Time Perspective: Prospective
Number Enrolled: 99999
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT01351545
75 Recruiting Novel Psychosocial Influences on Smoking Cessation
Condition: Smoking
Intervention: Other: Tobacco Dependence Treatment
Study Type: Observational
Phase:
Funder Type: Other
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Number Enrolled: 250
Gender: Female
Age Groups: Adult / Senior
NCT Number: NCT02173938
76 Recruiting Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design:
Number Enrolled: 600
Gender: Both
Age Groups: Child / Adult / Senior
NCT Number: NCT01005368
77 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 747
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01041703
78 Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 332
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01415752
79 Recruiting Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Biological: ofatumumab
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 100
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01190449
80 Recruiting Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
Condition: Malignant Mesothelioma
Interventions: Drug: pemetrexed disodium;   Other: clinical observation
Study Type: Interventional
Phase: Phase 2
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Primary Purpose: Treatment;   Masking: Open Label
Number Enrolled: 96
Gender: Both
Age Groups: Adult / Senior
NCT Number: NCT01085630

Indicates status has not been verified in more than two years